Physician profile
Stephen Thomas
NPI 1326584095
$13,193.42
in general payments reported to CMS, 2019-2025
17 companies · $789 in 2025
The $789 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $1,785 · 2023: $2,977 · 2024: $7,030 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,622 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,915 · Travel and Lodging: $1,885 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,621.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,915.00 |
| Travel and Lodging | $1,884.66 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $8,453.91 | 2022-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $1,601.43 | 2021-2025 | Vafseo, Auryxia |
| Amgen INC. | $977.64 | 2021-2024 | Parsabiv, Aranesp, Tavneos |
| Ardelyx, INC. | $706.30 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $584.55 | 2021-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $266.54 | 2021-2025 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $140.19 | 2021-2023 | Jynarque |
| Baxter Healthcare | $125.00 | 2022 | |
| Nxstage Medical, INC. | $67.12 | 2022 | |
| Calliditas Therapeutics US INC. | $54.96 | 2022 | |
| Glaxosmithkline, LLC. | $53.77 | 2021-2023 | |
| Horizon Therapeutics Plc | $51.66 | 2023 | Krystexxa |
| Novo Nordisk INC | $40.24 | 2024 | |
| Organogenesis INC. | $19.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.92 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $18.25 | 2023 | Lupkynis |
| Medtronic, INC. | $13.71 | 2024 | Ellipsys Vascular Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.